| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Preparing for anticipated bezuclastinib launch in GIST; PDUFA action date November 30, 2026 |
| 02 Sep 2026 |
8-K: Entry into a Material Definitive Agreement
On September 1, 2026, Cogent Biosciences, Inc. (the “Company”) entered into a Commercial Supply Agreement (the “Agreement”) with Hovione FarmaCiencia S.A. (“Hovione”) to manufacture bezuclastinib spray-dried dispersion and bezuclastinib ... |
| 10 Aug 2026 |
8-K: Other Events
We have examined the Registration Statement on Form S-3 (the “Registration Statement”) of Cogent Biosciences, Inc., a Delaware corporation (the “Company”), filed with the Securities and Exchange Commission (the “Commission”) pursuant to ... |
| 10 Aug 2026 |
8-K: Results of Operations and Financial Condition
On track for potential approval of bezuclastinib for GIST patients (PDUFA November 30) and NonAdvSM patients (PDUFA December 30) later this year; AdvSM New Drug Application submitted to FDA on June 30 |
| 11 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
At the Annual Meeting, each of the Company’s director nominees was elected and each of the other proposals voted on were approved. The final voting results are set forth below. |
| 05 May 2026 |
8-K: Results of Operations and Financial Condition
Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST) |
| 17 Feb 2026 |
8-K: Results of Operations and Financial Condition
SUMMIT NDA for bezuclastinib in patients with NonAdvSM submitted in December 2025; APEX NDA submission for bezuclastinib in patients with AdvSM on track for 1H 2026 |
| 08 Dec 2025 |
8-K: Other Events
On December 6, 2025 and December 8, 2025, Cogent Biosciences, Inc. (the “Company”) presented the full results from its SUMMIT clinical trial of bezuclastinib in patients with nonadvanced systemic mastocytosis (“NonAdvSM”) and announced p... |
| 18 Nov 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
We have acted as counsel to Cogent Biosciences, Inc., a Delaware corporation (the “Company”), in connection with the preparation and filing with the Securities and Exchange Commission (the “Commission”) of a Registration Statement on For... |
| 13 Nov 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
Cogent Biosciences, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom Jefferies LLC and J.P. Morgan Securities LLC are acting as... |
| 10 Nov 2025 |
8-K: Regulation FD Disclosure; Other Events
Exhibit 99.1 Peak Trial: Bezuclastinib + Sunitinib in Gastrointestinal Stromal Tumors (GIST) Top-Line Results Investor Webcast November 10, 2025 |
| 03 Nov 2025 |
8-K: Results of Operations and Financial Condition
Phase 3 PEAK results in 2nd-line GIST patients expected in November; pivotal APEX results in AdvSM patients expected in December |
| 11 Sep 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
THIS INSTRUMENT IS AN INDENTURE OF LEASE in which the Landlord and the Tenant are the parties hereinafter named, and which relates to space in the building known as 180 CityPoint and having an address at 180 Third Avenue, Waltham, Massac... |
| 05 Aug 2025 |
8-K: Results of Operations and Financial Condition
Reported positive top-line results from SUMMIT evaluating bezuclastinib in patients with NonAdvanced Systemic Mastocytosis, achieving statistical significance across all primary and key secondary endpoints |
| 10 Jul 2025 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition
Cogent Biosciences, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom J.P. Morgan Securities LLC, Leerink Partners LLC and Gugge... |
| 07 Jul 2025 |
8-K: Other Events
On July 7, 2025, Cogent Biosciences, Inc. (the “Company”) announced positive top-line results from the registration-directed Part 2 of the SUMMIT clinical trial of bezuclastinib in patients with non-advanced systemic mastocytosis (“NonAd... |
| 11 Jun 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
Facility provides additional funding for next steps of the Company’s growth, including the expected launch of bezuclastinib in 2026 |
| 05 Jun 2025 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders +1 more
Cogent Biosciences, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: |
| 06 May 2025 |
8-K: Results of Operations and Financial Condition
Three Registration-Directed Top-line Data Readouts Remain on Track in 2025: |
| 25 Feb 2025 |
8-K: Results of Operations and Financial Condition
Top-line results from SUMMIT trial in NonAdvSM patients expected July 2025 |
Loading...